Mitchell Garrison
Impact in
-
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
-
- Marine Sponges and Natural Products
Papers in
- Oncology 10
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 4
- Colorectal Cancer Treatments and Studies 2
- Bone health and treatments 1
-
- Lymphoma Diagnosis and Treatment 3
- Co-authors
- Lisa A. Hammond (3 shared papers)Eric K. Rowinsky (6 shared papers)Johann S. de Bono (2 shared papers)Julie C. Smith (3 shared papers)Christopher B. Jones (2 shared papers)Anthony W. Tolcher (4 shared papers)Geoffrey R. Weiss (3 shared papers)Steve Weitman (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Investigational New Drugs (1 paper)Clinical Breast Cancer (1 paper)Clinical Cancer Research (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United StatesGermany
In The Last Decade
Mitchell Garrison
12 papers receiving 162 citations
Peers
Comparison fields: 5 of 47
- Oncology 100
- Biotechnology 21
- Pathology and Forensic Medicine 34
- Cancer Research 21
- Toxicology 4
Countries citing papers authored by Mitchell Garrison
This map shows the geographic impact of Mitchell Garrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Garrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Garrison more than expected).
Fields of papers citing papers by Mitchell Garrison
This network shows the impact of papers produced by Mitchell Garrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Garrison. The network helps show where Mitchell Garrison may publish in the future.
Co-authors
The 25 scholars most cited alongside Mitchell Garrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 45 | |
| 2 | 2010 | 35 | |
| 3 | 2018 | 29 | |
| 4 | 2008 | 25 | |
| 5 | A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies. | 2003 | 14 |
| 6 | 2001 | 5 | |
| 7 | 2004 | 3 | |
| 8 | 2004 | 2 | |
| 9 | 2005 | 2 | |
| 10 | 2008 | 1 | |
| 11 | 2004 | 1 | |
| 12 | 2002 | 1 |
About Mitchell Garrison
Mitchell Garrison is a scholar working on Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Small Animals and Molecular Biology, having authored 12 papers that have together received 163 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), HER2/EGFR in Cancer Research (4 papers), Lymphoma Diagnosis and Treatment (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Treatments and Mutations (2 papers), Infectious Diseases and Mycology (2 papers), Breast Cancer Treatment Studies (1 paper) and Bone health and treatments (1 paper). The work is most often cited by research in Oncology (100 citations), Biotechnology (21 citations), Pathology and Forensic Medicine (34 citations), Cancer Research (21 citations) and Toxicology (4 citations). Mitchell Garrison has collaborated with scholars based in United States and Germany. Frequent co-authors include Lisa A. Hammond, Eric K. Rowinsky, Johann S. de Bono, Julie C. Smith, Christopher B. Jones, Anthony W. Tolcher, Geoffrey R. Weiss, Steve Weitman, Peter L. Bonate and Chris H. Takimoto. Their work appears in journals such as Journal of Clinical Oncology, Investigational New Drugs, Clinical Breast Cancer, Clinical Cancer Research and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.